Sponsored content brought to you by
Speed is a critical differentiator in therapeutic development. For teams developing DNA and RNA therapeutics, non-viral gene therapies, viral vectors, cell-free protein synthesis workflows, or CRISPR gene editing, shortening the design-to-test cycle can be the defining factor in program success.
Many therapeutic DNA development pipelines still rely on plasmid DNA produced through E. coli fermentation. While familiar and well-established, this process introduces delays and operational complexity that are increasingly at odds with rapid design–build–test cycles.
There is a need for innovation in DNA manufacturing as advanced therapies for common diseases move into clinical pipelines. The primary constraint is not just capacity, but also scalable processes that ensure robust quality, safety, and regulatory compliance, while minimizing cost.
Cell-free dbDNA
(doggybone) technology is a fundamentally different path forward with significant benefits. The dbDNA technology replaces bacterial fermentation in plasmid-based systems with enzymatic synthesis, thereby cutting timelines and costs. Manufacturing is simplified by removing many constraints associated with traditional plasmid workflows, while delivering a cleaner DNA starting material for downstream RNA and DNA therapeutic applications.
The limitations of plasmid DNA manufacturing
Conventional plasmid production, even at a small scale, requires transforming bacteria, picking colonies, growing overnight cultures, purifying plasmids, and performing restriction digests before the DNA is ready for downstream use. This can be a rate-limiting step, especially at the early stages of project development, when multiple constructs are screened in parallel.
At a larger scale, this process also includes complex cell-banking steps, a reliance on large-scale fermentation systems, and management of host-cell impurities (host-cell DNA/protein and endotoxin control). Production-scale DNA manufacturing can take weeks to months, adding time, cost and risk.
What is dbDNA?
Generated through cell-free synthesis, dbDNA is linear double-stranded DNA with covalently closed hairpin ends, produced entirely through enzymatic synthesis.
Because dbDNA is generated without a bacterial host, it eliminates the drawbacks of working with plasmid systems, such as the presence of bacterial backbone sequences and antibiotic resistance markers, as well as endotoxins associated with gram-negative bacterial production. The end result is cleaner DNA material for therapeutic workflows.
The EnClose Cell-free dbDNA synthesis workflow combines the robust phi29-XT DNA Polymerase for high-yield rolling circle amplification (RCA) and TelN Protelomerase for deconcatenation and covalent closure of linear dsDNA ends, in a streamlined, one-day process. This enzymatic approach eliminates challenges associated with plasmid systems, enabling teams to move quickly from bench to clinic.
RNA therapeutics and IVT templates
Using dbDNA technology, an IVT template can be generated in ~24 hours with only 1.5 hours of hands-on time. By comparison, linearized plasmid production can take 3 to 4 days with significantly more hands-on time for bacterial culture, plasmid purification, and restriction digestion.
Use of dbDNA eliminates plasmid backbone sequences, reduces endotoxin and bioburden risk, and enables maintenance of long or repetitive elements such as poly(A) tails.
The enzymatic workflow enables seamless transition from DNA assembly to dbDNA synthesis without bacterial transformation or overnight culture. The faster design-build-test cycle allows more time for optimization of untranslated regions, coding sequences, and delivery formats, and enables multi-gram manufacturing in weeks versus months.
DNA therapeutics and vector workflows
For DNA therapeutics and viral vector manufacturing, dbDNA offers a simplified cell-free enzymatic workflow, elimination of bacterial sequences, lower endotoxin and contamination risks, a smaller laboratory footprint, and reduced regulatory burden.
The removal of microbial dependencies makes dbDNA appealing for early-stage DNA therapeutic programs, including AAV and lentiviral payload production, and other applications where clean DNA and rapid iteration are critical.
By reducing DNA production timelines from months to days, dbDNA accelerates early development with faster iterations and high-throughput screening, reduces operational complexity and footprint, simplifies regulatory pathways, and ultimately moves promising candidates to the clinic sooner.
To learn more, visit www.neb.com/E9301.
ENCLOSE is a trademark of New England Biolabs, Inc.
DOGGYBONE and dbDNA are trademarks of Touchlight Genetics.
The post Cell-free DNA Synthesis of dbDNA™ for a Faster Path to RNA and DNA Therapeutics appeared first on GEN – Genetic Engineering and Biotechnology News.
